EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.
  • Home
  • About Us
    全部 Introduction Team Corporate Honors History
  • Pipeline
  • Technology
  • News
  • Job
  • Contact

  1. Home
  2. News

National high-tech enterprises

2020-10-10 10:01:19 admin 22

益科思特(北京)科技医药科技发展有限公司官网

In 2020, in this period of epidemic, we will fight the epidemic together and unite as one. The epidemic is merciless and there is love in the world. With the strong support of the state and the efforts of all the staff of IKEST, our company stood out from more than 2000 enterprises and won the honor of national high-tech enterprise.


  • Previous : Series A financing of Detong Capital and Qianhai Master Fund
  • Next : Top 50 of the "Maker Beijing 2020" epidemic prevention and control special competition
  • News

为你推荐

  • Innovative bispecific antibody YKST02 officially started Phase I clinical trial
  • First in human (FIH) dosing completed for YKST02, a bispecific antibody drug for multiple myeloma immunotherapy in Phase I clinical trial
  • The IND application for YKST02 has been approved, and Phase I clinical trials will start soon
  • The signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held
  • NHL/ALL Immunotherapy Candidate Double Antibody YK012 Phase I Clinical Trial Completed First Subject Administration

版权所有 2017-2026 京ICP备17063430号

5 Kaituo Road, Haidian District, Beijing (Zhongguancun Bio-medicine Park) Room B306-308

18910977588

Powered by  MetInfo  7.5.0